Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Experts urge early detection & better access to care
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Subscribe To Our Newsletter & Stay Updated
